Attached files
file | filename |
---|---|
EX-10.25 - EX-10.25 - vTv Therapeutics Inc. | vtvt-ex1025_142.htm |
10-K - 10-K - vTv Therapeutics Inc. | vtvt-10k_20191231.htm |
EX-32.2 - EX-32.2 - vTv Therapeutics Inc. | vtvt-ex322_7.htm |
EX-32.1 - EX-32.1 - vTv Therapeutics Inc. | vtvt-ex321_6.htm |
EX-31.2 - EX-31.2 - vTv Therapeutics Inc. | vtvt-ex312_9.htm |
EX-31.1 - EX-31.1 - vTv Therapeutics Inc. | vtvt-ex311_13.htm |
EX-21.1 - EX-21.1 - vTv Therapeutics Inc. | vtvt-ex211_8.htm |
EX-10.26 - EX-10.26 - vTv Therapeutics Inc. | vtvt-ex1026_143.htm |
EX-4.3 - EX-4.3 - vTv Therapeutics Inc. | vtvt-ex43_144.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
(1) |
Registration Statement (Form S-8 No. 333-206335) pertaining to the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan, and |
|
(2) |
Registration Statement (Form S-3 No. 333-223269) of vTv Therapeutics Inc., and |
|
(3) |
Registration Statement (Form S-3 No. 333-232571) of vTv Therapeutics Inc.; |
of our report dated February 20, 2020 with respect to the consolidated financial statements of vTv Therapeutics Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Raleigh, North Carolina
February 20, 2020